News for Healthier Living

Risk for GERD is higher with GLP-1 RA use compared to SGLT-2 inhibitor use

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors on the risk for gastroesophageal reflux disease (GERD) and its complications in patients with type 2 diabetes.

July 14, 2025


July 14 2025

July 13 2025

July 12 2025

July 11 2025

July 10 2025

July 9 2025

July 8 2025

July 7 2025

July 6 2025

July 5 2025

July 4 2025

July 3 2025

July 2 2025

July 1 2025